(MedPage Today) — CHICAGO — Incorporating the investigational, oral selective estrogen receptor degrader (SERD) camizestrant at the first sign of emerging ESR1 mutations extended the benefit of first-line therapy in hormone receptor (HR)-positive…
Source link : https://www.medpagetoday.com/meetingcoverage/asco/115837
Author :
Publish date : 2025-06-01 12:00:00
Copyright for syndicated content belongs to the linked Source.
